Lv4
534 积分 2022-10-24 加入
The discovery of potent small molecule activators of human STING
5天前
已完结
Activation of STING by targeting a pocket in the transmembrane domain
5天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
27天前
已完结
Discovery of Pyrazolo[1,5,4-de]quinoxalin-2(3H)-one Derivatives as Highly Potent and Selective PARP1 Inhibitors
2个月前
已完结
An exatecan derivative based linker-payload platform leads to ADC products with promising anti-tumor efficacy and potential low interstitial lung disease (ILD) risk
2个月前
已完结
Evaluation of Double Self-Immolative Linker-Based Antibody–Drug Conjugate FDA022-BB05 with Enhanced Therapeutic Potential
3个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
3个月前
已完结
In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia
3个月前
已完结
Evaluating the In Vitro Inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in Predicting Drug-Induced Hyperbilirubinemia
3个月前
已完结
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor
3个月前
已完结
皖公网安备34019202002308
